Clinical Trial Update: Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial evaluating WT1-specific donor-derived T cells after T-cell–depleted allogeneic stem cell transplantation in relapsed/refractory mu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• WT1-specific donor-derived T cells

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED